A few years back the government funded a clinical study of two drugs — one very expensive and the other not so much — to treat a leading cause of blindness. But the problems along the way should give everyone pause about how hard it will really be to figure out which medicines and treatments are better values, the idea behind so-called comparative effectiveness research.